Few companies have had a deeper influence on the orthotics and prosthetics sector than Hanger. What began with one amputee’s personal response to limb loss in the American Civil War grew into one of the most recognizable names in O&P, helping define how prosthetic and orthotic care is delivered, scaled and commercialized in the modern era. Hanger traces its roots to 1861, when founder James Edward “J.E.” Hanger lost his leg and went on to create an improved artificial limb, laying the foundation for what the company describes as more than 160 years of O&P innovation.
That founding story matters because Hanger’s early development reflects one of the central themes of the entire O&P profession: innovation born directly from patient need. According to Hanger’s corporate history, J.E. Hanger’s personal experience drove him to develop better prosthetic solutions for others with limb loss. Over time, the company evolved from a prosthetic maker into a much larger clinical and commercial platform spanning patient care, component distribution, education and research.
The company’s long-term effect on the market came not only from its age, but from its scale. In the United States, Hanger built one of the largest integrated O&P networks through clinic expansion and acquisitions. In SEC filings, the company stated that its Patient Care segment accounted for about 21% of the U.S. O&P clinic market in 2020 and about 24% in 2021. It also reported hundreds of clinic locations, including 697 patient care clinics and 104 satellite locations in 2019. That level of concentration made Hanger more than just a provider; it became one of the key reference points for how large-scale O&P service delivery could be organised.
Hanger’s model was especially important because it linked clinical care with distribution. Through Southern Prosthetic Supply (SPS), the company also became a major distributor of O&P components, serving both its own clinics and independent providers. In earlier SEC filings, Hanger described SPS as the largest distributor of branded and private-label O&P devices and components in the United States, and noted that its distribution arm supplied the broader market as well as internal operations. This gave Hanger influence not only over patient care delivery, but also over supply channels, purchasing patterns and product availability across the profession.
That integration had broader market consequences. It helped reinforce a more corporatised O&P model in which care delivery, procurement, inventory management and business administration could be consolidated at scale. For independent clinics around the world, Hanger became an example, and in some cases a warning, of how quickly the sector could move from artisan, founder-led practices toward regional and national provider platforms. This is partly an inference from Hanger’s structure and market share, but it is well supported by the company’s sustained acquisition activity and integrated operating model. Hanger’s filings show repeated acquisition of O&P businesses over many years, including multiple deals in 2021 and 2022 alone.
Clinically, Hanger also helped normalize the idea that O&P providers should operate as organized healthcare businesses rather than simply fabrication shops. Its growth coincided with rising expectations around outcomes, payer relations, compliance, documentation and multidisciplinary care. The company’s public filings repeatedly frame its work around acute, post-acute and patient care clinic settings, showing how O&P increasingly positioned itself within mainstream healthcare delivery rather than as a stand-alone trade.
Its influence extended into research and education as well. Hanger says its history includes involvement with major prosthetic advances such as microprocessors, carbon fiber, accelerometers, robotics and advanced socket materials. While Hanger did not invent all of those technologies, its scale and clinical footprint helped speed adoption of new systems once they became commercially viable. The company’s research and education activity, including the Hanger Institute for Clinical Research and Education, also reinforced the role large providers can play in evidence generation, clinician training and outcomes-based practice development.
From a global market perspective, Hanger’s importance is not that it directly dominates every country. It does not. Its strongest footprint has been in the United States. But its influence has still been global in three important ways.
First, it helped establish the scaled clinic-network model that many investors, provider groups and healthcare systems now recognize in O&P. Second, it demonstrated the commercial value of combining clinical care with distribution and adjacent services. Third, it showed how large O&P organizations can use size to shape standards around documentation, payer engagement, training and technology adoption. Those lessons have travelled well beyond the U.S. market, especially as consolidation, reimbursement pressure and private-equity interest have expanded internationally. This is an informed market interpretation based on Hanger’s documented structure and industry position.
Hanger also helped move the perception of O&P from a fragmented niche to a more investable healthcare category. Its years as a public company gave investors, analysts and strategic buyers a clearer view into O&P revenues, margins, reimbursement dependence, acquisition economics and service-line expansion. That visibility mattered. It made the sector easier to understand financially and more legible to institutional capital. In 2022, Hanger completed its acquisition by Patient Square Capital, marking another phase in the financial evolution of large O&P providers.
For the wider global market, that shift has had mixed effects. On one hand, larger corporate platforms can bring stronger systems, broader access to technology, better purchasing leverage and more formalized quality processes. On the other hand, consolidation can increase pressure on smaller independent clinics, centralize purchasing decisions and tilt the market toward scale-driven operating models. Hanger’s history captures both sides of that equation. It has been a driver of professionalization and modernization, but also a symbol of how O&P has increasingly become part of a larger healthcare business environment. This conclusion is interpretive, but it follows directly from the company’s history of market share, acquisitions, integrated distribution and investor ownership.
The bigger lesson is that Hanger did not just grow with the O&P sector. It helped shape the structure of the sector itself. From J.E. Hanger’s original prosthetic limb in 1861 to one of the largest clinic and distribution networks in the profession, the company’s history mirrors the transformation of orthotics and prosthetics from a craft-based field into a modern healthcare industry. For global O&P stakeholders, Hanger remains one of the clearest case studies of how scale, technology, reimbursement, research and consolidation can change the market.